Pfizer to seek emergency approval for its COVID vaccine

The answer to the coronavirus, which has infected just under 56 million people globally, may be just a couple critical weeks away.

Pfizer and its partner BioTech will seek emergency authorisation for its COVID-19 vaccine which was 95 per cent effective in its phase 3 trial.

Pfizer said today its COVID-19 vaccine is 95 per cent effective in preventing infections, even in older adults, an improvement of the initial data which gave it a 90 per cent efficiency rate two weeks ago.

The Phase 3 trial success means that Pfizer and its German partner BioTech, will seek an emergency use authorisation from the US Food and Drug Administration in the coming days.

Regarding the Phase 3 trial, which began with 43,661 volunteers on July 27, Pfizer said “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94 per cent.”

The 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina will continue to collect information about efficacy and safety for two more years.